FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a conjugate of fused protein of coagulation factor VIII with polyalkylene glycol for prevention or treatment of hemorrhagic diseases, a pharmaceutical composition for prevention or treatment of hemorrhagic diseases, and a method for prevention or treatment of hemorrhagic diseases. In one implementation option, the conjugate contains an active component of coagulation factor VIII with an amino acid sequence SEQ ID NO: 1 or 2, and polyalkylene glycol is branched polyalkylene glycol with molecular weight of 40 kDa.
EFFECT: invention expands the arsenal of remedies for prevention or treatment of hemorrhagic diseases.
10 cl, 15 dwg, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| PREPARATION CONTAINING VIII FACTOR AND VON WILLEBRAND FACTOR PEPTIDES | 2015 |
|
RU2714154C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
| IMPROVED FACTOR IX FUNCTION PROTEIN AND ITS CONJUGATE AND THEIR USE | 2020 |
|
RU2794350C1 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| PHARMACEUTICAL COMPOSITIONS OF PEGYLATED LIPOSOMES AND COAGULATION FACTORS | 2015 |
|
RU2737291C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
